Infectious Disease Molecular Diagnostics Market
The worldwide diagnostics sector is changing due to the need for quicker and more precise testing for infectious diseases. New opportunities for healthcare providers and diagnostic enterprises are being created by advancements in PCR, digital PCR, multiplex testing, next-generation sequencing (NGS), and point-of-care diagnostics.
The market for infectious disease molecular diagnostics was estimated to be worth USD 16.85 billion in 2025 and is expected to grow at a compound annual growth rate (CAGR) of 6.06% from 2026 to 2035, reaching USD 30.35 billion.
What Is Fueling the Market for Molecular Diagnostics?
Early and precise diagnosis is becoming more important due to the rising prevalence of infectious diseases like HIV, TB, hepatitis, respiratory infections, and STDs.
Molecular testing is becoming quicker and more thorough at the same time due to technological advancements. Reagents and kits accounted for the largest product sector with a 68% share in 2025, while real-time PCR (qPCR) continued to be the top technology with 63% of the market.
The increasing use of multiplex and syndromic testing, which can detect several diseases from a single sample, is another significant trend. This can facilitate quicker clinical decision-making and assist medical practitioners in choosing the best course of action.
Point-of-Care Testing Generates New Prospects
Conventional laboratory testing may call for specialized equipment and qualified staff. Testing is becoming more accessible to patients thanks to point-of-care molecular diagnostics.
It is anticipated that diagnostic technology companies would have substantial potential due to the growing need for quick testing in hospitals, emergency rooms, outpatient clinics, and settings with limited resources.
Digital health integration and artificial intelligence are also becoming significant development areas. AI-enabled technologies can facilitate data processing, quicker reporting, automated result interpretation, and improved laboratory workflow.
Asia Pacific is expected to see strong growth.
North America is now the largest regional market, accounting for 35.10 percent of worldwide market share in 2025. However, Asia Pacific is becoming a more important growing market.
The Asia Pacific infectious disease molecular diagnostics market was valued at roughly USD 4.30 billion in 2025 and is expected to grow to around USD 9.26 billion by 2035, reflecting a 7.98% CAGR.
India is also displaying high development potential, thanks to expanding diagnostic laboratory networks, rising healthcare spending, an increase in infectious disease burden, and government disease surveillance activities.
What Does the Future Look Like?
The future of infectious disease molecular diagnostics is expected to be shaped by speedier testing, decentralized diagnostics, multiplex platforms, AI integration, digital PCR, and genomic technologies.
However, exorbitant technology prices, a lack of experienced laboratory staff, regulatory restrictions, and unequal access to advanced diagnostic facilities remain significant problems.
As healthcare systems prioritize early detection and disease surveillance, molecular diagnostics will continue to play a significant role in the global infectious disease management ecosystem.
Explore the Full Market Analysis.
Brandessence Market Research's Infectious Disease Molecular Diagnostics Market Report provides complete market size, forecasts, regional analysis, segmentation, competitive landscape, market drivers, constraints, opportunities, and technological trends.
